Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and ...
AN2 awarded third year of funding from Gates FoundationAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advanc...
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescr...
GSK's Q3 sales and earnings topped estimates, driven by Specialty Medicines and vaccines, prompting the firm to raise its 2...
GSK (NYSE:GSK) raises FY2025 Adj EPS guidance from $4.59 to $4.73-$4.81 vs $4.38 analyst estimate. Raises FY2025 sales outlook ...
GSK (NYSE:GSK) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.26 by 17.78 perce...
FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free...
